Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis

Tuberculosis is a leading cause of death in our country. Multidrug-resistant tuberculosis increases the morbidity and mortality due to severe manifestations and difficult and prolonged medications. Newer antitubercular drugs like delamanid have been approved by WHO in management of these cases, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Marwah, Vikas, Patil, Prashant R., Choudhary, Robin, Malik, Virender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894277/
https://www.ncbi.nlm.nih.gov/pubmed/36695263
http://dx.doi.org/10.4103/lungindia.lungindia_451_22
_version_ 1784881710572240896
author Marwah, Vikas
Patil, Prashant R.
Choudhary, Robin
Malik, Virender
author_facet Marwah, Vikas
Patil, Prashant R.
Choudhary, Robin
Malik, Virender
author_sort Marwah, Vikas
collection PubMed
description Tuberculosis is a leading cause of death in our country. Multidrug-resistant tuberculosis increases the morbidity and mortality due to severe manifestations and difficult and prolonged medications. Newer antitubercular drugs like delamanid have been approved by WHO in management of these cases, but the real-world experience of this drug is lacking in our country. We present our early experience of use of delamanid in extensively drug-resistant pulmonary tuberculosis.
format Online
Article
Text
id pubmed-9894277
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-98942772023-02-03 Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis Marwah, Vikas Patil, Prashant R. Choudhary, Robin Malik, Virender Lung India Case Report Tuberculosis is a leading cause of death in our country. Multidrug-resistant tuberculosis increases the morbidity and mortality due to severe manifestations and difficult and prolonged medications. Newer antitubercular drugs like delamanid have been approved by WHO in management of these cases, but the real-world experience of this drug is lacking in our country. We present our early experience of use of delamanid in extensively drug-resistant pulmonary tuberculosis. Wolters Kluwer - Medknow 2023 2022-12-29 /pmc/articles/PMC9894277/ /pubmed/36695263 http://dx.doi.org/10.4103/lungindia.lungindia_451_22 Text en Copyright: © 2022 Indian Chest Society https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Marwah, Vikas
Patil, Prashant R.
Choudhary, Robin
Malik, Virender
Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
title Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
title_full Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
title_fullStr Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
title_full_unstemmed Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
title_short Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
title_sort early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894277/
https://www.ncbi.nlm.nih.gov/pubmed/36695263
http://dx.doi.org/10.4103/lungindia.lungindia_451_22
work_keys_str_mv AT marwahvikas earlyexperienceofdelamanidinextensivelydrugresistantpulmonarytuberculosis
AT patilprashantr earlyexperienceofdelamanidinextensivelydrugresistantpulmonarytuberculosis
AT choudharyrobin earlyexperienceofdelamanidinextensivelydrugresistantpulmonarytuberculosis
AT malikvirender earlyexperienceofdelamanidinextensivelydrugresistantpulmonarytuberculosis

Ejemplares similares